2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)-
- CAS No.
- 1259519-20-4
- Chemical Name:
- 2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)-
- Synonyms
- Sutetinib;(E)-N-(3-cyano-7-ethoxy-4-((3-ethynylphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide;2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)-
- CBNumber:
- CB98387669
- Molecular Formula:
- C26H25N5O2
- Molecular Weight:
- 439.51
- MDL Number:
- MOL File:
- 1259519-20-4.mol
- MSDS File:
- SDS
Last updated:2025-04-18 09:53:10
2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Properties
| Boiling point | 665.8±55.0 °C(Predicted) |
|---|---|
| Density | 1.25±0.1 g/cm3(Predicted) |
| pka | 12.37±0.43(Predicted) |
| FDA UNII | 538A7S75AB |
2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-1180784 | Sutetinib 99.27% | 1259519-20-4 | 5mg | $271 | 2026-06-04 | Buy |
| ChemScene | CS-1180784 | Sutetinib 99.27% | 1259519-20-4 | 10mg | $433 | 2026-06-04 | Buy |
| ChemScene | CS-1180784 | Sutetinib 99.27% | 1259519-20-4 | 25mg | $877 | 2026-06-04 | Buy |
| ChemScene | CS-1180784 | Sutetinib 99.27% | 1259519-20-4 | 50mg | $1408 | 2026-06-04 | Buy |
| aablocks | AA02F8NW | SUTETINIB >98% | 1259519-20-4 | 5mg | $313 | 2026-06-03 | Buy |
2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Chemical Properties, Uses, Production
Uses
Sutetinib is an orally active inhibitor for tyrosine kinase, that is associated with tumor growth and angiogenesis, such as VEGFR (Ki= 0.009 μM for VEGFR-1/2/3), PDGFR (Ki= 0.008 μM for PDGFR-α/β) and proto-oncogene cKIT. Sutetinib inhibits the proliferation, migration, and tubular structure formation of endothelial cells and fibroblasts, and exhibits board-spectrum antitumor efficacy in vitro and in vivo[1].
References
[1] Hao Z, et al., Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016 Sep 8;9:5495-505. DOI:10.2147/OTT.S112242
2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Preparation Products And Raw materials
Raw materials
Preparation Products
2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)- Suppliers
Global Suppliers ( 4)
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Beckham Medical Technology Co., Ltd | 13816613772 | huahero21@sina.com | China | 2994 | 55 |
| ChengDu TongChuangYuan Pharmaceutical Co.Ltd | 028-83379370 13880556291 | tcy@tcypharm.com | China | 8696 | 58 |
| Suzhou Sino Rare Chemical Co., Ltd. | 512-62857507 | sales@sinorarechem.com | China | 1864 | 58 |
| TargetMol Chemicals Inc. | 15002134094 | marketing@targetmol.cn | China | 29874 | 58 |
1259519-20-4 (2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)-) Related Search:
2-Butenamide, N-[3-cyano-7-ethoxy-4-[(3-ethynylphenyl)amino]-6-quinolinyl]-4-(dimethylamino)-, (2E)-
Sutetinib
(E)-N-(3-cyano-7-ethoxy-4-((3-ethynylphenyl)amino)quinolin-6-yl)-4-(dimethylamino)but-2-enamide
1259519-20-4




